Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
· Expanded partnership will evaluate SMAC mimetic alone and in combination with anti-PD-1 immunotherapy for the treatment of solid tumours ·&nbs......